NOT-DA-19-059: Notice of Intent to Publish a Funding Opportunity Announcement for the Reissue NIDA Program Project Grant Applications (P01 Clinical Trial Optional)

Notice of Intent to Publish a Funding Opportunity Announcement for the Reissue NIDA Program Project Grant Applications (P01 Clinical Trial Optional)

Notice Number: NOT-DA-19-059

Key Dates

Release Date: July 19, 2019
Estimated Publication Date of Funding Opportunity Announcement: September 08, 2019
First Estimated Application Due Date: January 01, 2020
Earliest Estimated Award Date: January 01, 2020
Earliest Estimated Start Date: March 01, 2020

Related Announcements
PAR-18-425

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this notice is to inform potential applicates that National Institute on Drug Abuse (NIDA) intends to reissue PAR-18-425, NIDA Program Project Grant Applications (P01 Clinical Trial Optional).

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The FOA is expected to be published in September 2019 with an expected application due date in September 2019.

This FOA will utilize the P01 activity code.

Details of the planned FOA are provided below.

Research Initiative Details

This Notice encourages investigators with expertise and insights into the science of substance abuse and addiction to begin to consider applying for this new FOA.

In addition, collaborative investigations combining expertise in neuroscience, genetics, epigenetic, development, epidemiology, pharmacology, bioinformatics, toxicology and other fields relevant to addiction and substance use disorders will be encouraged and these investigators should also begin considering applying for this application.

Among the areas of research encouraged in this initiative are neuroscience, genetics, epigenetic, development, epidemiology, pharmacology, bioinformatics, toxicology research examining the mechanisms that underlie substance abuse disorders as well as research designed to improve the translation of existing knowledge of strategies for the prevention and treatment of substance use disorders

Funding Information

Estimated Total Funding TBD
Expected Number of Awards TBD
Estimated Award Ceiling TBD
Primary CFDA Numbers TBD

Anticipated Eligible Organizations

Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Regional Organization
Eligible Agencies of the Federal Government

Applications are not being solicited at this time.

Inquiries

Please direct all inquiries to:

Jonathan D. Pollock, Ph.D.
National Institute on Drug Abuse (NIDA)
301-435-1316
npilotte@mail.nih.gov

Kevin Walton, Ph.D.
Division of Therapeutics and Medical Consequences
National Institute on Drug Abuse)
Telephone: 301-827-5980
Email: waltonkm@nida.nih.gov

Meyer D. Glantz, Ph.D.
Division of Epidemiology, Services and Prevention Research
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6504
Email: mglantz@nida.nih.gov

Steven Grant, Ph.D.
Division of Neuroscience and Behavior
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-4877
Email: sgrant@nida.nih.gov